One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Worldwide Clinical Trials, San Antonio, Texas, United States
University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany
Dallas VA Medical Center, Dallas, Texas, United States
Stanford Cancer Institute, Palo Alto, California, United States
Research Site, Leeds, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.